[Clinical experiences with noxiptilin].
Noxiptilin (Elronon) proved to be a good bipolar thymoleptic agent in the clinical test at 3 special clinics. Its stimulating effect on the psychomotor function is more pronounced than its sedative action. Therefore, in cases with the anxious, agitated depressive syndrome the additional therapy with a neuroleptic agent or a sedative tranquilizer may be favourable. N. is well tolerated even at a higher age. The side effects are the same as those of other known thymoleptics.
D000275:Adjustment Disorders / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D003527:Cyclothymic Disorder / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy*; D003986:Dibenzocycloheptenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy
D003986:Dibenzocycloheptenes
Klinische Erfahrungen mit Noxiptilin